Unknown

Dataset Information

0

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis

ABSTRACT:

SUBMITTER: Zafar A 

PROVIDER: S-EPMC11536716 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
| S-EPMC8563380 | biostudies-literature
Unknown Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
| S-EPMC5642913 | biostudies-literature
Unknown Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
| S-EPMC7701512 | biostudies-literature
Unknown PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.
| S-EPMC10725960 | biostudies-literature
Unknown PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
| S-EPMC9806143 | biostudies-literature
Unknown Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
| S-EPMC8373810 | biostudies-literature
Unknown Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
| S-EPMC8107750 | biostudies-literature
Unknown Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
| S-EPMC10550157 | biostudies-literature
Unknown PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.
| S-EPMC5414865 | biostudies-literature
Unknown A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
| S-EPMC9898180 | biostudies-literature